| The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) RIG Holt, JH DeVries, A Hess-Fischl, IB Hirsch, MS Kirkman, T Klupa, ... Diabetes care 44 (11), 2589-2625, 2021 | 602 | 2021 |
| Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised … P Dandona, C Mathieu, M Phillip, L Hansen, SC Griffen, D Tschöpe, ... The lancet Diabetes & endocrinology 5 (11), 864-876, 2017 | 303 | 2017 |
| International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium–glucose cotransporter (SGLT) inhibitors T Danne, S Garg, AL Peters, JB Buse, C Mathieu, JH Pettus, ... Diabetes care 42 (6), 1147-1154, 2019 | 302 | 2019 |
| COVID-19 severity is tripled in the diabetes community: a prospective analysis of the pandemic’s impact in type 1 and type 2 diabetes JM Gregory, JC Slaughter, SH Duffus, TJ Smith, LM LeStourgeon, ... Diabetes care 44 (2), 526-532, 2021 | 281 | 2021 |
| Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study P Dandona, C Mathieu, M Phillip, L Hansen, D Tschöpe, F Thorén, J Xu, ... Diabetes Care 41 (12), 2552-2559, 2018 | 224 | 2018 |
| Insulin expression and C-peptide in type 1 diabetes subjects implanted with stem cell-derived pancreatic endoderm cells in an encapsulation device AMJ Shapiro, D Thompson, TW Donner, MD Bellin, W Hsueh, J Pettus, ... Cell Reports Medicine 2 (12), 2021 | 201 | 2021 |
| Clinical implications of real-time and intermittently scanned continuous glucose monitoring SV Edelman, NB Argento, J Pettus, IB Hirsch Diabetes Care 41 (11), 2265-2274, 2018 | 186 | 2018 |
| Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes K Cusi, F Bril, D Barb, D Polidori, S Sha, A Ghosh, K Farrell, NE Sunny, ... Diabetes, Obesity and Metabolism 21 (4), 812-821, 2019 | 160 | 2019 |
| Incidences of severe hypoglycemia and diabetic ketoacidosis and prevalence of microvascular complications stratified by age and glycemic control in US adult patients with type … JH Pettus, FL Zhou, L Shepherd, R Preblick, PR Hunt, S Paranjape, ... Diabetes care 42 (12), 2220-2227, 2019 | 150 | 2019 |
| Recommendations for using real-time continuous glucose monitoring (rtCGM) data for insulin adjustments in type 1 diabetes J Pettus, SV Edelman Journal of diabetes science and technology 11 (1), 138-147, 2017 | 125 | 2017 |
| Morning administration of 0.4 U/kg/day insulin glargine 300 U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin … TS Bailey, J Pettus, R Roussel, W Schmider, M Maroccia, N Nassr, ... Diabetes & metabolism 44 (1), 15-21, 2018 | 119 | 2018 |
| The past, present, and future of basal insulins J Pettus, T Santos Cavaiola, WV Tamborlane, S Edelman Diabetes/metabolism research and reviews 32 (6), 478-496, 2016 | 112 | 2016 |
| A real-world prospective study of the safety and effectiveness of the loop open source automated insulin delivery system JW Lum, RJ Bailey, V Barnes-Lomen, D Naranjo, KK Hood, RA Lal, ... Diabetes technology & therapeutics 23 (5), 367-375, 2021 | 107 | 2021 |
| Initial clinical evaluation of VC-01TM combination product—a stem cell–derived islet replacement for type 1 diabetes (T1D) RR Henry, J Pettus, JON Wilensky, AMJ SHAPIRO, PA Senior, B Roep, ... Diabetes 67 (Supplement_1), 2018 | 97 | 2018 |
| CD8 T-cell reactivity to islet antigens is unique to type 1 while CD4 T-cell reactivity exists in both type 1 and type 2 diabetes G Sarikonda, J Pettus, S Phatak, S Sachithanantham, JF Miller, ... Journal of autoimmunity 50, 77-82, 2014 | 96 | 2014 |
| Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled … M von Herrath, SC Bain, B Bode, JO Clausen, K Coppieters, L Gaysina, ... The Lancet Diabetes & Endocrinology 9 (4), 212-224, 2021 | 95 | 2021 |
| Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects RR Henry, S Mudaliar, TP Ciaraldi, DA Armstrong, P Burke, J Pettus, ... Diabetes Care 37 (9), 2609-2615, 2014 | 75 | 2014 |
| How patients with type 1 diabetes translate continuous glucose monitoring data into diabetes management decisions J Pettus, DA Price, SV Edelman Endocrine Practice 21 (6), 613-620, 2015 | 73 | 2015 |
| Rates of hypoglycemia predicted in patients with type 2 diabetes on insulin glargine 300 U/ml versus first-and second-generation basal insulin analogs: the real-world LIGHTNING … J Pettus, R Roussel, F Liz Zhou, Z Bosnyak, J Westerbacka, R Berria, ... Diabetes Therapy 10, 617-633, 2019 | 70 | 2019 |
| Challenges associated with insulin therapy in type 2 diabetes mellitus S Edelman, J Pettus The American journal of medicine 127 (10), S11-S16, 2014 | 70 | 2014 |
